NICE has assessed 10 ways of testing for epidermal growth factor receptor tyrosine kinase (EGFR–TK) mutations in the tumours of adults with untreated non-small-cell lung cancer (NSCLC) that has spread, to help the NHS decide whether to use these tests and which ones to use.

NSCLC is the commonest type of lung cancer. The tests are useful in detecting who might benefit from treatment with EGFR–TK inhibitors (anticancer drugs that target specific tumour cells in patients with mutated forms of the EGFR–TK gene) rather than chemotherapy.

NICE has recommended 5 ways of testing as options, but it was unable to decide on the other 5 because there wasn’t enough evidence.

Your responsibility

This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected to take this guidance fully into account. However, the guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

Commissioners and/or providers have a responsibility to implement the guidance, in their local context, in light of their duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity, and foster good relations. Nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties.

Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.

  • National Institute for Health and Care Excellence (NICE)